This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

35/100

✓ Peer-reviewed alzhub usefulness score 35 out of 100. Mild cognitive impairment

Topic: Brain proteins, microglia and lab models

Plain-language summary

Alzheimer’s disease (AD) remains a significant global health challenge with limited FDA-approved treatments, necessitating the search for novel preventive strategies. Antioxidants that are present in fruits and vegetables have garnered attention due to their potential neuroprotective effects. Among these, pomegranate (Punica granatum L.) has emerged as a promising source of neuroprotective antioxidants as it is rich in polyphenols, flavonoids, and hydrolysable tannins. Pomegranate seed oil (PSO) is a source of bioactive compounds that may modulate key pathological processes of AD. This study investigated the therapeutic potential of PSO in murine neuroblastoma N2a cells treated with lipopolysaccharide (LPS) to simulate AD-like inflammation. The effects of PSO on inflammation and oxidative stress markers, including TNF-α, iNOS, SOD1, and IL1β, were evaluated, along with changes in AD-related biomarkers Aβ42, Aβ40, and p-tau181. Additionally, the study extended its findings to clinical settings by assessing the impact of supervised PSO consumption for 12 months on similar biomarkers in patients with mild cognitive impairment. Results from this integrative approach demonstrated the anti-inflammatory and antioxidant potential of PSO, supporting its role in modulating AD-associated pathophysiology. These findings suggest that PSO may serve as an early-stage intervention to delay or mitigate AD progression, highlighting its therapeutic potential in preclinical and clinical contexts.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Tzekaki, E. E., Katsipis, G., Chatzikostopoulos, A., Koutoupa, A., Lavrentiadou, S. N., Tsolaki, M., et al. (2025). Neuroprotective, Antioxidant and Anti-Inflammatory Effect of Greek Pomegranate Seed Oil on N2a Neuroblastoma Cells and Mild Cognitive Impairment Patients. Biology. https://doi.org/10.3390/biology14050548

Vancouver

Tzekaki EE, Katsipis G, Chatzikostopoulos A, Koutoupa A, Lavrentiadou SN, Tsolaki M, et al. Neuroprotective, Antioxidant and Anti-Inflammatory Effect of Greek Pomegranate Seed Oil on N2a Neuroblastoma Cells and Mild Cognitive Impairment Patients. Biology. 2025. doi:10.3390/biology14050548. PMID: 40427737.

BibTeX

@article{tzekaki2025-40427737,
  author  = {Tzekaki, Elena E. and Katsipis, Georgios and Chatzikostopoulos, Athanasios and Koutoupa, Anna and Lavrentiadou, Sophia N. and Tsolaki, Magda and Pantazaki, Αnastasia A.},
  title   = {{Neuroprotective, Antioxidant and Anti-Inflammatory Effect of Greek Pomegranate Seed Oil on N2a Neuroblastoma Cells and Mild Cognitive Impairment Patients}},
  journal = {Biology},
  year    = {2025},
  doi     = {10.3390/biology14050548},
  pmid    = {40427737},
  url     = {https://doi.org/10.3390/biology14050548}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record names 7 authors; APA and Vancouver show the first six, BibTeX and the downloads carry all of them. Check the citation against the original before you use it.

How to read this study

Design: our record does not state a study design, so check the methods section of the original before weighing the result.
Size: the record gives no participant count. Look for one in the original before trusting a pattern.
Effect: the record gives no effect size, so the summary above cannot say how large any difference was.

What the evidence grade means here

This page is graded low. alzhub.org assigns the grade automatically from keywords in the abstract, not from reading the paper. Low means the abstract matched neither pattern. It is the default label, and it does not mean the work is poor; many sound lab and imaging papers land here. It can add at most 5 of the 100 points in the study score, and it is a label about design, not a verdict on whether the findings are true.

New to reading papers? Six questions to ask of any Alzheimer’s study · how we score.

Key findings

Alzheimer’s disease (AD) remains a significant global health challenge with limited FDA-approved treatments, necessitating the search for novel preventive strategies.
Results from this integrative approach demonstrated the anti-inflammatory and antioxidant potential of PSO, supporting its role in modulating AD-associated pathophysiology.
These findings suggest that PSO may serve as an early-stage intervention to delay or mitigate AD progression, highlighting its therapeutic potential in preclinical and clinical contexts.

Why it matters

In cells and in patients with mild cognitive impairment, pomegranate seed oil showed anti-inflammatory and antioxidant potential and effects on Alzheimer's-related biomarkers. The findings suggest it may serve as an early-stage intervention to delay or mitigate Alzheimer's progression, though the evidence is described as supporting a possible role rather than proven benefit.

Study details

Evidence strengthLow

How this study scored 35/100

Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomized / blinded because the record does not state it.

Component	Points	Why
Journal tier	7 / 10	Tier 3 — peer-reviewed journal (Biology)
Journal's citation record	1 / 4	Biology: journal h-index 134 (OpenAlex, 2026-10-29)
Study design	0 / 12	No study design recorded — scores zero, not guessed (not stated in the record — scored 0)
Strength of evidence	1 / 5	Rated “low” in our summary
Peer-review validation	10 / 10	Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent	4 / 5	2025 — within 3 year(s) of the newest study here
Sample size	0 / 4	Participant count not stated — scores zero (not stated in the record — scored 0)
Effect reported	0 / 3	No effect size reported — scores zero (not stated in the record — scored 0)
Studied in people	0 / 3	Not stated whether this was studied in people — scores zero (not stated in the record — scored 0)
Randomized / blinded	0 / 2	No randomization or blinding stated — scores zero (not stated in the record — scored 0)
Times cited	1 / 7	Cited 3 times (OpenAlex, 2026-10-10)
Citations per year	1 / 5	1.0 citations a year over 3 year(s) since 2025
Impact for its field and year	2 / 6	Cited 1.7× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here	0 / 6	No other study in this library cites it
Still being cited	1 / 4	Cited 3 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record	2 / 4	Last-listed author Αnastasia A. Pantazaki: h-index 41 (OpenAlex, whole career)
Institution's track record	0 / 3	Aristotle University of Thessaloniki: institution h-index 560 (OpenAlex)
Multicenter collaboration	1 / 3	OpenAlex lists 2 institution(s) in 1 country
Indexed in PubMed	2 / 2	Indexed in PubMed (PMID 40427737)
Free to read	2 / 2	Free to read
Total	35 / 100	—

What each of these 20 components measures, and what this score is not →

Read the original

Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).

Studies in the library that share something with this one. The line above each title says what.

Studies this one cites

Referenced by this study and also in the alzhub library, so you can read them here.

Related studies in Mild cognitive impairment from nearby years

Also tagged “tdp-43”

1,150 studies in the library carry the topic tag “tdp-43”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 1,150 tagged studies.

Studies sharing this one's topic tags

Similar studies

More on Mild cognitive impairment

See all studies in Mild cognitive impairment →